Product NewsGemacBio announces the successful conclusion of Phase IIa clinical trials for its new molecule designed to treat multiple sclerosis
Product NewsSYMPHOGEN’S SUCCESS IN MANUFACTURING CONSISTENT BATCHES OF POLYCLONAL ANTIBODIES FOR CLINICAL TRIALS ATTRACTS NEW USD 25 MILLION INVESTMENT